Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Toronto Dominion Bank

Toronto Dominion Bank boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 134,202 shares of the pharmaceutical company's stock after purchasing an additional 3,096 shares during the period. Toronto Dominion Bank owned approximately 0.05% of Vertex Pharmaceuticals worth $62,415,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of VRTX. Groesbeck Investment Management Corp NJ boosted its position in Vertex Pharmaceuticals by 1.2% in the second quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company's stock valued at $841,000 after buying an additional 21 shares during the last quarter. Mutual Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company's stock valued at $1,751,000 after acquiring an additional 21 shares during the last quarter. Institute for Wealth Management LLC. increased its stake in shares of Vertex Pharmaceuticals by 0.6% in the second quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company's stock worth $1,681,000 after acquiring an additional 22 shares during the period. Drive Wealth Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 2.0% during the second quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company's stock worth $516,000 after purchasing an additional 22 shares during the last quarter. Finally, Daymark Wealth Partners LLC lifted its position in Vertex Pharmaceuticals by 2.8% during the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company's stock valued at $374,000 after purchasing an additional 22 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded down $4.17 during midday trading on Thursday, reaching $464.12. 956,574 shares of the stock were exchanged, compared to its average volume of 1,186,074. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $473.12 and a 200 day simple moving average of $475.88. Vertex Pharmaceuticals Incorporated has a twelve month low of $372.80 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.69 billion. During the same quarter last year, the firm earned $3.67 earnings per share. The firm's quarterly revenue was up 11.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of a number of recent research reports. UBS Group upped their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Oppenheimer decreased their target price on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an "outperform" rating for the company in a research note on Wednesday, October 30th. HC Wainwright restated a "buy" rating and set a $600.00 price target on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Jefferies Financial Group raised shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating and increased their target price for the stock from $500.00 to $550.00 in a research note on Monday. Finally, Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a "sector perform" rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $506.20.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.